Literature DB >> 8636365

Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas.

D Russo1, F Arturi, H G Suarez, M Schlumberger, J A Du Villard, U Crocetti, S Filetti.   

Abstract

Forty-four thyroid autonomously hyperfunctioning adenomas were analyzed to assess the frequency of mutations occurring in the TSH receptor (TSHR). PCR-amplified fragments encompassing the entire exon 10 of the TSHR gene were obtained from the genomic DNA extracted from the tumors and their adjacent normal tissues and were examined by direct nucleotide sequencing. Point mutations were found in 9 of the 44 adenomas examined (20%). One mutation occurred in codon 619 (Asp to Gly), four in codon 623 (three were Ala to Ser, one Ala to Val substitution), two in codon 632 (both Thr to Ile), and two in codon 633 (Asp to Tyr or His). All the alterations were located in a part of the gene coding for an area including the third intracellular loop and the sixth transmembrane domain of the TSH receptor. All mutations were somatic and heterozygotic, and none was simultaneous with alterations of ras or gsp oncogenes. Thus, our data show that in our series of 44 hyperfunctioning thyroid adenomas, a somatic mutation of the TSHR, responsible for the constitutive activation of the cAMP pathway, occurs in 20% of the tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636365     DOI: 10.1210/jcem.81.4.8636365

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.

Authors:  Ya-Xiong Tao
Journal:  Pharmacol Ther       Date:  2008-08-09       Impact factor: 12.310

Review 2.  Molecular insights into TSH receptor abnormality and thyroid disease.

Authors:  D Russo; F Arturi; E Chiefari; S Filetti
Journal:  J Endocrinol Invest       Date:  1997-01       Impact factor: 4.256

3.  Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor.

Authors:  P Kopp; S Muirhead; N Jourdain; W X Gu; J L Jameson; C Rodd
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas.

Authors:  F Cetani; M Tonacchera; A Pinchera; R Barsacchi; F Basolo; P Miccoli; F Pacini
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

5.  Levothyroxine therapy in preventing nodular recurrence after hemithyroidectomy: a retrospective study.

Authors:  M Alba; D Fintini; R M Lovicu; R M Paragliola; G Papi; C A Rota; A Pontecorvi; S M Corsello
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

Review 6.  Objective assessment of cancer genes for drug discovery.

Authors:  Mishal N Patel; Mark D Halling-Brown; Joseph E Tym; Paul Workman; Bissan Al-Lazikani
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

Review 7.  Coherent somatic mutation in autoimmune disease.

Authors:  Kenneth Andrew Ross
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

8.  Structure and activation of the TSH receptor transmembrane domain.

Authors:  Ricardo Núñez Miguel; Jane Sanders; Jadwiga Furmaniak; Bernard Rees Smith
Journal:  Auto Immun Highlights       Date:  2016-12-05

9.  The insulin and igf-I pathway in endocrine glands carcinogenesis.

Authors:  Roberta Malaguarnera; Alaide Morcavallo; Antonino Belfiore
Journal:  J Oncol       Date:  2012-08-08       Impact factor: 4.375

10.  How genetic errors in GPCRs affect their function: Possible therapeutic strategies.

Authors:  Henriette Stoy; Vsevolod V Gurevich
Journal:  Genes Dis       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.